NTEC - Intec Pharma Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.8000
+0.4000 (+9.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.4000
Open4.4000
Bid4.2500 x 2900
Ask6.0000 x 900
Day's Range4.2000 - 4.8500
52 Week Range3.5500 - 9.8000
Volume256,056
Avg. Volume93,995
Market Cap159.485M
Beta1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.5370
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • PR Newswire14 hours ago

    Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society

    JERUSALEM , Sept. 25, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that three posters in support of the Company's Phase 3 clinical ...

  • PR Newswire6 days ago

    Intec Pharma to Participate at Upcoming Investment Conferences

    JERUSALEM , Sept. 20, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...

  • PR Newswirelast month

    Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update

    Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study JERUSALEM , Aug. 15, 2018 /PRNewswire/ --   Intec Pharma ...

  • Investopedia2 months ago

    5 Favorite Biotech Bets

    Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.

  • PR Newswire3 months ago

    Intec Pharma Appoints William Bradley Hayes to Board of Directors

    Intec Pharma Ltd. (NTEC) (NTEC.TA) ("Intec" or "the Company") today announces the appointment of William Bradley Hayes (Brad) to the Company's Board of Directors.  Mr. Hayes was formerly Executive Vice President, Chief Financial Officer and Treasurer of Laboratory Corporation of America Holdings (LabCorp), a diagnostics laboratory company with current annual revenue of approximately $10 billion.  Mr. Hayes will chair the Board's audit committee.  With this appointment, Intec's Board has been expanded to eight directors, including seven who are independent. "We are especially pleased to have Brad join the Intec Board of Directors.

  • PR Newswire4 months ago

    Intec Pharma to Present at Jefferies 2018 Healthcare Conference

    Intec Pharma Ltd. (NASDAQ:NETC) (NTEC) ("Intec" or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City. Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website, where it will also be archived for a period of time. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.

  • PR Newswire4 months ago

    Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update

    More than 350 patients enrolled in pivotal Phase 3 ACCORDANCE trial and more than 80% of eligible patients entered the open label extension study JERUSALEM , May 15, 2018 /PRNewswire/ -- Intec Pharma Ltd. ...

  • ACCESSWIRE5 months ago

    Blog Exposure - Intec Pharma Shares Phase-1 PK and Safety Data from Accordion Pill Carbidopa/Levodopa at AAN Annual Meeting

    LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on Intec Pharma Ltd (NASDAQ: NTEC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NTEC as the Company's latest news hit the wire. On April 24, 2018, the Company, which is a clinical-stage biopharmaceutical organization focused on developing drugs based on its proprietary Accordion Pill platform technology, declared that it presented data from two Phase-1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease at the American Academy of Neurology 2018 Annual Meeting (AAN 2018), in Los Angeles.

  • PR Newswire5 months ago

    Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting

    Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were highlighted in a poster presentation at the American Academy of Neurology 2018 Annual Meeting (AAN 2018) underway in Los Angeles. The poster titled, "Optimizing Delivery of Carbidopa/Levodopa via the Accordion Pill: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers," was delivered by R. Michael Gendreau, M.D., Ph.D. Chief Medical Officer of Intec Pharma, last evening at AAN.

  • PR Newswire5 months ago

    Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares

    Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of 6.75 million of its ordinary shares, at a public offering price of $5.25 per ordinary share, for gross proceeds of approximately $35.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes.

  • PR Newswire5 months ago

    Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares

    JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share. Intec Pharma has granted the underwriters a 30-day option to purchase up to approximately 1.0 million additional ordinary shares to cover over-allotments. Intec Pharma intends to use the net proceeds from the offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes.

  • PR Newswire6 months ago

    Intec Pharma Announces Proposed Public Offering of Ordinary Shares

    JERUSALEM, April 10, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) (NTEC) today announced the launch of an underwritten public offering of its ordinary shares. In connection with this offering, Intec Pharma also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares being offered to cover over-allotments. All ordinary shares in the offering are being offered by Intec Pharma.

  • PR Newswire6 months ago

    Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting

    JERUSALEM, April 4, 2018 /PRNewswire/ -- Intec Pharma LTD (NTEC) (NTEC) ("Intec" or "the Company") today announces that data collected from the Company's Phase 2 development program of its proprietary Accordion Pill™ oral drug delivery system have been accepted for poster presentation at the American Academy of Neurology 2018 Annual Meeting (AAN 2018) taking place April 21 – 27, 2018 in Los Angeles.

  • PR Newswire6 months ago

    Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease

    The event will feature presentations by KOLs C. Warren Olanow, MD, Mount Sinai School of Medicine, and Karl Kieburtz, MD, MPH, University of Rochester, who will discuss the current treatment landscape and unmet medical need for treating patients with Parkinson's Disease. Intec Pharma's lead product candidate, the Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, is in Phase 3 clinical trials for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

  • PR Newswire6 months ago

    Intec Pharma Appoints Roger J. Pomerantz, M.D. to Board of Directors

    Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors. Dr. Pomerantz is President, Chief Executive Officer and Chairman of the Board of Directors of Seres Therapeutics, Inc. With this appointment, Intec's board has seven directors including six whom are independent. Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances.

  • PR Newswire6 months ago

    Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson's Disease

    Intec Pharma Ltd. (NASDAQ, TASE: NTEC) ("Intec" or the "Company") today announces that it has partnered with LTS Lohmann Therapie-Systeme AG ("LTS") for the manufacture of the Company's lead product candidate, Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) as a treatment for the severe symptoms in advanced Parkinson's Disease patients. Under the agreement, LTS will manufacture the AP-CD/LD capsules using Intec's proprietary Accordion Pill production technology in LTS' manufacturing facility in Andernach, Germany upon the completion of assembly of the production line.

  • PR Newswire7 months ago

    Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update

    More than 300 patients enrolled in pivotal Phase 3 ACCORDANCE Trial Gastroscopy safety sub-study successfully completed JERUSALEM , March 9, 2018 /PRNewswire/ --   Intec Pharma LTD (NASDAQ: NTEC) (TASE: ...

  • PR Newswire7 months ago

    Intec Pharma, Ltd. to Present at Four Investor Conferences in March

    JERUSALEM , March 5, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion ...

  • PR Newswire8 months ago

    Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer

    JERUSALEM, Jan. 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, today announced it has named R. Michael Gendreau, M.D., Ph.D. to the position of Chief Medical Officer. Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.

  • PR Newswire9 months ago

    Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company

    Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals to explore using the Accordion Pill platform for a proprietary Novartis compound. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill™ technology. "We are delighted to work with Novartis in potentially utilizing our Accordion Pill platform technology," said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma.

  • Investopedia9 months ago

    Pot Stock Winners of the Week

    Despite the cannabis sector taking a beating last week, these four stocks rose more than 5%.

  • PR Newswire9 months ago

    Intec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / Levodopa

    Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion PillTM platform technology, today announced that the Canadian Intellectual Property Office has issued a Certificate of Grant of a Canadian patent No. 2,721,493. The patent, entitled "Carbidopa/Levodopa Gastroretentive Drug Delivery," broadly covers the Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa and provides patent protection through April 2029. The patent belongs to the Company's IN-7 patent family, which already includes patents granted in the U.S., Europe, China, Japan, South Korea, Hong Kong, South Africa, and Israel.

  • PR Newswire10 months ago

    Intec Pharma Reports Third Quarter 2017 Operating and Financial Results

    · Closed equity offering of $57.5 million ; Cash of $64.7 million at September 30, 2017 · Expanding planned enrollment to 420 patients in its Phase 3 ACCORDANCE Trial; enrollment to be completed in the ...

  • PR Newswire11 months ago

    Intec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare Conference

    JERUSALEM , November 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform ...